Using Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: A Cost-Utility Analysis in Spain

Value in Health

Volumn 7, Issue 1, 2004, Pages 52-60

  Latour Pérez, Jaime ^a   Navarro Ruiz, Andrés ^a   Ridao López, Manuel ^b   Cervera Montes, Manuel ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b Generalitat Valenciana   (Spain)

^c Hospital Peset   (Spain)

Author keywords

Clopidogrel; Coronary disease; Cost benefit analysis; Decision support techniques; Myocardial infarction; Platelet aggregation inhibitors; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION THEORY; DIAGNOSIS RELATED GROUP; DRUG COST; ECONOMICS; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SPAIN;

EID: 0442293653     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2004.71313.x     Document Type: Article

References (22)

1. Yusuf S, Zhao F, Mehta SR, et al. The clopidogrel in unstable angina to prevent recurrent events trial investigators: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
2. Lamy A, Chrolavicius S, Gafni A, et al. The cost-effectiveness of the use of clopidogrel in acute coronary syndromes based upon the CURE study. Circulation Suppl 2002;106:758.
3. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1339-41.
4. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-8.
5. Instituto Nacional de Estadistica. INEbase. Madrid: Istituto Nacional de Estadistica (cited September 12, 2002). Available from http://ine.es.p. 12-9-2002.
6. Guidry UC, Evans JC, Larson MG, et al. Temporal trends in event rates after Q-wave myocardial infarction The Framingham Heart Study. Circulation 1999;100:2054-9.
7. Eckman MH, Levine HJ, Salem DN, Pauker SG. Making decisions about antithrombotic therapy in heart disease. decision analytic and cost-effectiveness issues. Chest 1998;114(Suppl):S699-714.
8. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102.
9. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995;10:321-30.
10. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996;94:957-65.
11. Estadisticas de referencia estatal de los sistemas de agrupación de registros de pacientes (GDR), 1999. Madrid, Ministerio de Sanidad y Consumo (cited September 12, 2002). Available from http-// www.msc.es/cmbd/publicaciones
12. Tree Age Software. DATA Pro: Healthcare User's Manual. Williamson (MA): Tree Age Software, 2001.
13. Hunink M, Glasziou P. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge: Cambridge University Press, 2001.
14. Sox HC, Blatt MA, Higgins MC, Marton KI. Medical Decision-Making. Stoneham: Butterworths, 1988.
15. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision-making. JAMA 2000;284: 835-42.
16. Budaj A, Yusuf S, Metha SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002;106:1622-6.
17. Hunink M, Bult JR, de Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 2002;18:337-46.
18. Puig J, Pinto J, Dalmau E. El Valor Monetario de la Salud. Barcelona: Springer-Verlag Ibérica, 2001.
19. Sacristan JA, Oliva J, del Llano J, et al. GAT is an efficient health care technology in Spain? Gac Sanit 2002;16:334-43.
20. Metha SR, Yusuf S, Peters RJG. Effect of pretreatment with clopidogrel and aspirin folllowed by long-term therapy in patients undergoing percutaneous coronary interventions. Lancet 2001;358: 527.
21. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
22. Nara W, Ashley I, Rosner F. Thrombotic thrombocytopenic purpura associated with clopidogrel administration: case report and brief review. Am J Med Sci 2001;322:170-2.